NCT00137826View on ClinicalTrials.gov

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

July 31, 2009

Conditions
Mesothelioma
Interventions
DRUG

Erlotinib

Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.

DRUG

Bevacizumab

Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.

Trial Locations (3)

60637

The University of Chicago, Chicago

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

University of Chicago

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00137826 - Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma | Biotech Hunter | Biotech Hunter